Complement evasion by Borrelia burgdorferi

伯氏疏螺旋体的补体逃避

基本信息

项目摘要

DESCRIPTION (provided by applicant): Pathogenic spirochetes most often associated with human Lyme disease have been grouped into three genospecies, B. burgdorferi, B. afzelii, and B. garinii. Interestingly, all three genospecies seem to populate different niches during persistent infection, which ultimately results in different clinical manifestations. For example, B. burgdorferi and B. afzelii are commonly associated with disease involving the joints and skin, respectively, while B. garinii typically causes central nervous system abnormalities. The underlying mechanism that results in the different tissue tropisms and disease manifestations between genospecies is not clear. However, it was recently shown that both B. burgdorferi and B. afzelii bind host serum complement inhibitor factor H on their cell surface, which confers complement resistance. By contrast, B. garinii does not bind factor H and is complement sensitive, which has led to the hypothesis that B. garinii organisms persistently infect the central nervous system because it is an environment limited in cytotoxic complement. Recently, several B. burgdorferi outer surface lipoproteins (Osp) were identified by us and others that can bind factor H in vitro. The factor H binding proteins identified include several lipoproteins related to OspE as well as a borrelial protein designated BbA68. To further these prior studies, and more directly examine the actual role that factor H-binding proteins play in complement resistance, we inactivated the bbA68 gene in an avirulent strain of B. burgdorferi. While the wild type parental strain is fully complement resistant, the mutant that lacked expression of BbA68 was found to be highly complement sensitive, suggesting that this protein may be the major molecule that imparts complement resistance to B. burgdorferi. To further examine the contribution of BbA68 in complement resistance of Borrelia spp. during an actual infection (i.e., in vivo), we propose to (i) inactivate the bbA68 gene in a virulent strain of B. burgdorferi and (ii) over express BbA68 in a virulent, complement sensitive B. garinii isolate. The mutant strains generated will then be examined for changes in virulence and/or disease pathogenesis using the mouse model of Lyme disease. The combined studies outlined in this R21 application focus on providing the necessary foundation and preliminary data for a future R01 application that will examine the functional role of BbA68 in spirochete tissue tropism and Lyme disease pathogenesis.
描述(由申请人提供):最常与人类莱姆病相关的致病性螺旋体分为三个基因种,B。burgdorferi,B. afzelii和B. garinii。有趣的是,所有三个基因种似乎在持续感染期间占据不同的小生境,这最终导致不同的临床表现。例如,B。burgdorferi和B.阿氏杆菌通常分别与涉及关节和皮肤的疾病相关,而B.伽氏病通常引起中枢神经系统异常。导致基因种之间不同组织向性和疾病表现的潜在机制尚不清楚。然而,最近的研究表明,这两个B。burgdorferi和B. Afzelii在其细胞表面上结合宿主血清补体抑制因子H,这赋予补体抗性。相比之下,B. Garinii不结合因子H,并且是补体敏感的,这导致了B.加里尼氏微生物持续感染中枢神经系统,因为它是一个细胞毒性补体有限的环境。最近,几家B. Burgdorferi外表面脂蛋白(Osp)被我们和其他人鉴定为可以在体外结合因子H。所鉴定的H因子结合蛋白包括与OspE相关的几种脂蛋白以及命名为BbA 68的疏螺旋体蛋白。为了进一步这些先前的研究,并更直接地检查因子H结合蛋白在补体抗性中发挥的实际作用,我们灭活了B的无毒菌株中的bbA 68基因。burgdorferi。虽然野生型亲本菌株是完全补体抗性的,但发现缺乏BbA 68表达的突变体是高度补体敏感的,表明该蛋白质可能是赋予B补体抗性的主要分子。burgdorferi。为了进一步研究BbA 68在疏螺旋体属的补体抗性中的贡献。在实际感染期间(即,in vivo),我们提出(i)在B的强毒株中克隆bbA 68基因。burgdorferi和(ii)在毒性补体敏感性B中过表达BbA 68。加里尼分离株。然后使用莱姆病小鼠模型检查产生的突变株的毒力和/或疾病发病机制的变化。R21申请中概述的联合研究重点是为未来的R 01申请提供必要的基础和初步数据,该申请将研究BbA 68在螺旋体组织嗜性和莱姆病发病机制中的功能作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DARRIN R. AKINS其他文献

DARRIN R. AKINS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DARRIN R. AKINS', 18)}}的其他基金

UNDERGRADUATE/OUTREACH CORE
本科/拓展核心
  • 批准号:
    8359641
  • 财政年份:
    2011
  • 资助金额:
    $ 21.98万
  • 项目类别:
ADMINISTRATIVE CORE
行政核心
  • 批准号:
    8359640
  • 财政年份:
    2011
  • 资助金额:
    $ 21.98万
  • 项目类别:
Outer membrane proteins of Borrelia burgdorferi
伯氏疏螺旋体的外膜蛋白
  • 批准号:
    8332895
  • 财政年份:
    2011
  • 资助金额:
    $ 21.98万
  • 项目类别:
ADMINISTRATIVE CORE
行政核心
  • 批准号:
    8167550
  • 财政年份:
    2010
  • 资助金额:
    $ 21.98万
  • 项目类别:
Surface Lipoproteins and Serum Resistance in Borrelia burgdorferi
伯氏疏螺旋体的表面脂蛋白和血清耐药性
  • 批准号:
    8075005
  • 财政年份:
    2010
  • 资助金额:
    $ 21.98万
  • 项目类别:
UNDERGRADUATE/OUTREACH CORE
本科/拓展核心
  • 批准号:
    8167551
  • 财政年份:
    2010
  • 资助金额:
    $ 21.98万
  • 项目类别:
Surface Lipoproteins and Serum Resistance in Borrelia burgdorferi
伯氏疏螺旋体的表面脂蛋白和血清耐药性
  • 批准号:
    7991080
  • 财政年份:
    2010
  • 资助金额:
    $ 21.98万
  • 项目类别:
Oklahoma IDeA Network of Biomedical Research Excellence
俄克拉荷马州 IDeA 生物医学研究卓越网络
  • 批准号:
    7892151
  • 财政年份:
    2009
  • 资助金额:
    $ 21.98万
  • 项目类别:
Oklahoma IDeA Network of Biomedical Research Excellence
俄克拉荷马州 IDeA 生物医学研究卓越网络
  • 批准号:
    7900220
  • 财政年份:
    2009
  • 资助金额:
    $ 21.98万
  • 项目类别:
Complement evasion by Borrelia burgdorferi
伯氏疏螺旋体的补体逃避
  • 批准号:
    7230023
  • 财政年份:
    2006
  • 资助金额:
    $ 21.98万
  • 项目类别:

相似海外基金

Immune Modulation During Acute Lyme Disease Infection as the Result of Aberrant Immunoglobulin Glycosylation
异常免疫球蛋白糖基化导致急性莱姆病感染期间的免疫调节
  • 批准号:
    10726417
  • 财政年份:
    2023
  • 资助金额:
    $ 21.98万
  • 项目类别:
Defining the host and pathogen determinants of peptidoglycan induced pathophysiology in Lyme disease
定义莱姆病肽聚糖诱导的病理生理学的宿主和病原体决定因素
  • 批准号:
    10566961
  • 财政年份:
    2023
  • 资助金额:
    $ 21.98万
  • 项目类别:
Auto-antibodies as predictive markers for Post treatment Lyme Disease Syndrome
自身抗体作为治疗后莱姆病综合征的预测标记
  • 批准号:
    10737996
  • 财政年份:
    2023
  • 资助金额:
    $ 21.98万
  • 项目类别:
Neuroimaging and blood markers in post treatment Lyme disease with persistent neurologic symptoms
具有持续神经系统症状的莱姆病治疗后的神经影像学和血液标记物
  • 批准号:
    10745421
  • 财政年份:
    2023
  • 资助金额:
    $ 21.98万
  • 项目类别:
ImmunoPET Probes for the Imaging of Lyme Disease
用于莱姆病成像的免疫PET探针
  • 批准号:
    10802275
  • 财政年份:
    2023
  • 资助金额:
    $ 21.98万
  • 项目类别:
Determinants of Post-Treatment Phenotypes in Lyme Disease
莱姆病治疗后表型的决定因素
  • 批准号:
    10738012
  • 财政年份:
    2023
  • 资助金额:
    $ 21.98万
  • 项目类别:
Elucidating the contributions of c-di-GMP and PlzA to tick- and mammalian host-adaptation in Lyme disease spirochetes
阐明 c-di-GMP 和 PlzA 对莱姆病螺旋体蜱和哺乳动物宿主适应的贡献
  • 批准号:
    10739945
  • 财政年份:
    2023
  • 资助金额:
    $ 21.98万
  • 项目类别:
The natural release of unusual peptidoglycan fragments drives persistent Lyme disease symptoms in susceptible hosts
异常肽聚糖片段的自然释放导致易感宿主持续出现莱姆病症状
  • 批准号:
    10736544
  • 财政年份:
    2023
  • 资助金额:
    $ 21.98万
  • 项目类别:
Unlocking serology’s secrets: harnessing novel immune biomarkers to predict Lyme disease progression and recovery
揭开血清学的秘密:利用新型免疫生物标志物来预测莱姆病的进展和恢复
  • 批准号:
    10737313
  • 财政年份:
    2023
  • 资助金额:
    $ 21.98万
  • 项目类别:
PlzA, cyclic-di-GMP and the enzootic cycle for Lyme disease
PlzA、环二 GMP 和莱姆病的地方性循环
  • 批准号:
    10608622
  • 财政年份:
    2022
  • 资助金额:
    $ 21.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了